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Abstract
There has been much effort to prioritize genomic variants with respect to their impact on
“function”. However, function is often not precisely defined: sometimes it is the disease
association of a variant; on other occasions, it reflects a molecular effect on transcription or
epigenetics. Here, we coupled multiple genomic predictors to build GRAM, a GeneRAlized
Model, to predict a well-defined experimental target: the expression-modulating effect of a
non-coding variant on its associated gene, in a transferable, cell-specific manner. Firstly, we
performed feature engineering: using LASSO, a regularized linear model, we found tran-
scription factor (TF) binding most predictive, especially for TFs that are hubs in the regula-
tory network; in contrast, evolutionary conservation, a popular feature in many other variant-
impact predictors, has almost no contribution. Moreover, TF binding inferred from in vitro
SELEX is as effective as that from in vivo ChIP-Seq. Second, we implemented GRAM inte-
grating only SELEX features and expression profiles; thus, the program combines a univer-
sal regulatory score with an easily obtainable modifier reflecting the particular cell type. We
benchmarked GRAM on large-scale MPRA datasets, achieving AUROC scores of 0.72 in
GM12878 and 0.66 in a multi-cell line dataset. We then evaluated the performance of
GRAM on targeted regions using luciferase assays in the MCF7 and K562 cell lines. We
noted that changing the insertion position of the construct relative to the reporter gene gave
very different results, highlighting the importance of carefully defining the exact prediction
target of the model. Finally, we illustrated the utility of GRAM in fine-mapping causal variants
and developed a practical software pipeline to carry this out. In particular, we demonstrated
in specific examples how the pipeline could pinpoint variants that directly modulate gene
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expression within a larger linkage-disequilibrium block associated with a phenotype of inter-
est (e.g., for an eQTL).
Author summary
With advances in sequencing technologies, a deluge of genomic data is available; however,
only a fraction of non-coding genomic variants are functionally relevant. Sifting through
this data to prioritize genomic variants with respect to function is an important but chal-
lenging task. In this study, we built GRAM, a GeneRAlized Model, to predict the expres-
sion-modulating effects of non-coding variants in a cell-specific manner. GRAM
combines a universal regulatory score defined by transcription factor binding with an eas-
ily obtainable modifier defined by transcription factor binding and expression to reflect
the particular cell type. We evaluated this framework on multiple cell lines with high per-
formance and showed that it could be applied to any cell line or sample with gene expres-
sion data. We also integrated GRAM into a practical software pipeline to fine-map causal
variants that directly modulate gene expression among a larger linkage-disequilibrium
block associated with a phenotype of interest. GRAM complements other general variant
effect prediction methods–which often combine disparate features–by helping to precisely
define the subset of prioritized variants that directly alters gene expression.
Introduction
Advances in next-generation sequencing (NGS) technologies have enabled high-throughput
whole genome and exome sequencing [1], which have led to the identification and characteri-
zation of many disease-associated mutations [2] and the vast majority of common single
nucleotide variants (SNVs) in the human population [3, 4]. Genome-wide association studies
(GWAS) have found that these variants mostly lie outside of protein-coding regions [5],
emphasizing the functional importance of non-coding regulatory elements in the human
genome. These advances have also led to an urgent need to develop high-throughput methods
to sift through this deluge of sequencing data to quickly determine the functional relevance of
each non-coding variant [6].
Evidence suggests that only a fraction of non-coding variants are functional, and the major-
ity of functional variants show only modest effects [7]. Studies like GWAS [8] and expression
quantitative trait eQTL [9] have evaluated the association of variants with traits of interest
from a statistical perspective. In traditional GWAS and eQTL analyses, an association locus
may host the tag-SNPs and a number of linked variants that may potentially account for the
molecular mechanism underlying the association [10]. However, it remains difficult to distin-
guish those that are truly causal [11–13]. Thus, downstream analysis requires fine-mapping to
identify the true causal variants by integrating the external genetic and epigenetic information
[12, 14].
As association studies give little information about the mechanism of a variant’s effects, it
would be helpful to directly test the molecular effects of a large numbers of variants using
highly quantitative assays. Luciferase reporter assays are a common method to measure the
regulatory effects of functional elements [15]. Researchers can compare the difference of lucif-
erase expression with and without a mutation to estimate the experimental molecular effect of
non-coding variants lying in a functional element. By using high-throughput microarray and
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NGS technology, the massively parallel reporter assay (MPRA) has extended the scales to the
genome-wide level [16–21]. Recently, Tewhey and colleagues demonstrated the capability of
MPRA to identify the causal variants that directly modulated gene expression [22, 23]. This
study identified 842 expression-modulating variants (emVARs) showing significantly differen-
tial expression modulation effects and provided a high-quality data source for computational
modeling [22, 23].
There is an increasing need for computational methods to effectively predict the molecular
effects of variants and improve our understanding of the underlying biology of these effects.
Several approaches have been developed to address the problem of variant prioritization from
different perspectives. Based on the target of predictions, these methods roughly fall into three
major categories: 1) disease-causing effect predictors (e.g. GWAVA [24], and GenoSkyline
[25]), which aim to prioritize causal disease variants and distinguish them from benign ones;
2) fitness consequence prioritization tools (e.g., CADD [26], fitCons [27] and LINSIGHT
[28]), which attempt to identify the variants based on evolutionary fitness; 3) comprehensive
tools (e.g., DeepSEA [29], FunSeq2 [6], FUN-LDA [30]) which integrate multiple data sources
for prediction of functional variants. Many of these computational methods are designed to
predict and prioritize deleterious and disease-associated variants from a phenotypic perspec-
tive, but not to highlight specific molecular consequences of these variants (i.e., their effects on
the activities of functional elements). Moreover, some of these tools are cell type-agnostic, and
tools that are cell type-aware depend on cell type-specific data with somewhat limited availabil-
ity, such as ChIP-Seq or epigenetic features. Thus, it would be helpful to build a generalized
model that can be systematically specialized to any desired cell type with only a small amount
of easily obtainable cell type-specific information (e.g. expression data).
In this study, we addressed the problem of molecular effect prediction of variants from a
different perspective. Instead of predicting phenotypic consequences from genotypes, which is
a common practice, we aimed to directly predict the expression-modulating effect of the vari-
ants from various sources of information. Our model, named GRAM (i.e., GeneRAlized
Model), incorporates selected transcription factor (TF) binding information from in vitro
SELEX assays, representing the general binding affinity of TFs on the variant’s location, and
cell type-specific expression profiles, representing cellular contexts. Combining cell type-inde-
pendent and -dependent features makes our model both flexible and specific. When we evalu-
ated results from MPRA and luciferase assay experiments show our model achieved high
predictive performance and could be easily transferred to other cell types and assay platforms.
We also demonstrated the potential application of GRAM to the fine-mapping of pre-defined
variants in linkage disequilibrium. As a supplement to many general variant effect prediction
methods (which often combine disparate features), our model can help to precisely define the
subset of prioritized variants that directly alters gene expression. For instance, after using a
more general functional impact tool such as FunSeq or VEP [31, 32], one could use GRAM on
the prioritized variants to identify the subset that has a direct expression modulating effect (as
opposed to being prioritized for other reasons such as strong association with an organismal
phenotype). Furthermore, one could use GRAM to fine-map the key causal variant modulating
gene expression from the many variants in a linkage-disequilibrium block associated with
gene expression in an eQTL study.
Results
Overall analysis flow
In this study, we first collected a dataset from Tewhey et al. [22] to estimate expression modu-
lation differences between reference allele and mutants in the GM12878 cell line. This MPRA-
Predictive model for the cell-specific molecular effect of non-coding variants
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generated dataset contains 3,222 SNVs filtered by logSkew value, which measures the log-fold
change of the expression-modulating differences between reference and alternative alleles.
Among them, 792 variants (named emVARs) had a significant expression-modulating effect
compared with their respective reference allele, which indicates the molecular effect of the var-
iant. Here, we treated emVARs and non-emVARs as positive and negative dataset, respec-
tively, in our GRAM model.
As described in Fig 1, our GRAM model is implemented in three steps: (i) prediction of the
universal regulatory consequences of an element with variant using the SELEX TF binding
score; (ii) prediction of a cell type modifier score in a specific cellular context by combining TF
binding score with cell type-specific TF expression profiles; and (iii) estimation of the expres-
sion modulating effect in a cell type-specific context by integrating outputs from the previous
two steps.
Exploring conservation and TF binding features
We first investigated the potential of evolutionary conservation and transcription binding fea-
tures as predictors. Evolutionary conservation is associated with deleterious fitness conse-
quence and is widely used in prioritization algorithms of non-coding variants, such as PhyloP
[33] and PhastCons [34] scores in LINSIGHT [28] and CADD [26], and GERP [33] score in
FunSeq2 [6]. We performed comparative analyses for these three conservation features across
different datasets (S1 Fig). We found that the PhastCons and PhyloP patterns of emVARs and
non-emVARs are different from Human Gene Mutation Database (HGMD) [35] variants but
similar to non-HGMD variants, which are thought to be benign. GERP scores show a similar
pattern but have smaller variance in emVARs and non-emVARs compared to other datasets,
with slightly larger values for emVARs. As we did not find differential patterns when compar-
ing emVARs and non-emVARs, we further discovered that the correlation between logSkew
and all three conservation scores was low (close to 0) by linear regression. These results suggest
that the conservation scores might contribute little to the molecular effects under study that
focuses on expression modulation of variants in more conserved regions with homogeneous
evolutionary patterns.
TF binding can link the molecular effect of non-coding variants to a cascade of a regulatory
network, which is thought to be an important contributing factor to the variants’ regulatory
effects [26, 29, 36, 37]. Tewhey et al. found that the logSkew value positively associates with TF
binding scores. To thoroughly evaluate the effect of TF binding, we tested TF binding peaks
overlapping with the SNVs and TF motif break events in the Tewhey dataset. We annotated
and analyzed the emVAR and non-emVAR variant sets with FunSeq2 [6], and found that the
emVAR set had more TF binding events compared with the non-emVAR set (Fig 2A). In addi-
tion to TF binding enrichment, we examined the motif breaking scores for these TFs. After
removing TFs with insufficient observations, the differences between the distributions of
motif-break scores for alternative and reference alleles in emVARs are larger than those in the
non-emVAR dataset (Fig 2B). According to this analysis, the emVAR set tends to have not
only more TF binding events, but also larger binding alterations compared with the non-
emVAR set. Our results indicate that TF binding shows high association with the expression-
modulating effects of the variants and align with recent studies on the underestimated relative
importance of transcription [38, 39].
Model-based feature selection
We generated a candidate training feature set from the outputs of 515 DeepBind models for
TF binding, inferred from both ChIP-Seq [40] and in vitro SELEX assays [41], on the adjacent
Predictive model for the cell-specific molecular effect of non-coding variants
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sequences of the variant of interest. With a comprehensive feature selection framework for
selection of impactful TF binding features, we prioritized these features across models with
LASSO stability selection [42] and Random Forest (shown in Fig 3A). The 20 most important
features (out of 515) with respect to the mean importance across all methods is shown in
Fig 1. Overall flow of GRAM. The model predicts functional effects given the genotype in three steps: the first step predicts a universal regulatory activity using TF
binding features; the second step predicts a cell type-specific modifier score using the TF binding score and expression profiles; the final step integrates the results from
the previous two steps to predict the expression-modulating effect of the variant.
https://doi.org/10.1371/journal.pgen.1007860.g001
Predictive model for the cell-specific molecular effect of non-coding variants
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decreasing order in Fig 3A. Both ChIP-Seq and SELEX DeepBind features showed high impor-
tance, with the top two being GM12878 ChIP-Seq features (SP1 and BCL3), which are cell line
specific, followed by SELEX features starting with ETP63. The top-ranked impactful TFs tend
to have more protein-protein interactions than the bottom-ranked TFs, indicating that the
importance of a TF reflects its role in the TF-TF cascade regulatory network (Fig 3B).
Interestingly, many SELEX features, though not cell type dependent, achieved similar pre-
dictive power as cell type-specific ChIP-Seq features. We compared the predictive perfor-
mances of cell type-dependent ChIP-Seq features, cell type-independent SELEX features, and a
combination of both feature sets using a LASSO regressor, support vector machine (SVM)
regressor and Random Forest. Incorporating ChIP-Seq-derived features, though introducing
more cell type-specificity, did not boost the accuracy significantly for any of the three models
(Fig 3C and S1 Table). As the availability of ChIP-Seq data is restricted to a few cell lines (S2
Fig), we instead used SELEX features to build a more generalized model that can be easily
applied to different cell types.
We then used the features generated from disease-association prediction tools (CADD [43],
FunSeq2 [32], DeepSEA [44], GWAVA [45], LINSIGHT [46], and Eigen [47]) to predict the
same molecular effect target. As shown in Fig 3C, this analysis indicated that the prediction of
disease-associated variants is not equivalent to that of expression-modulating variants.
Fig 2. Preliminary selection of predictive features. (a) Enrichment of TF binding peaks in emVAR and non-emVAR sets. The x-axis represents a ratio of variants
overlapping with the TF peaks over all variants in the same set. The TFs are sorted by p-values in hypergeometric distribution test in an decreasing order. The number in
the bracket indicates the observed motif break event count. TFs with a sufficient number of observations are highlighted in bold. (b) Motif break scores in reference and
alternative alleles for TFs with sufficient observed event count.
https://doi.org/10.1371/journal.pgen.1007860.g002
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Building a generalized model by multi-step learning
Using the TF binding features from DeepBind models and the MPRA dataset from Tewhey
et al. [22], we implemented our multi-step model. In the first step, we predicted the universal
regulatory activity of an element with or without a variant. The 10-fold cross validation dem-
onstrated exemplary performance of the model with an area under the receiver operating char-
acteristic curve (AUROC) of 0.938 and an area under the precision-recall curve (AUPRC) of
0.928 (Fig 4A and S3 Fig).
Fig 3. Model based feature selection. (a) Importance of the top-ranked features for SELEX- and ChIP-Seq-derived models. The features are sorted according to the
mean of LASSO stability selection and Random Forest importance scores. (b) Regulatory network degree of relevant TFs for the top-ranked and bottom-ranked TFs in
LASSO stability selection and Random Forest. (c) Comparison of the performance of different feature sets, including cell-line specific ChIP-Seq TF binding scores and
SELEX TF binding scores, as well as features defined from previous disease-association prediction tools.
https://doi.org/10.1371/journal.pgen.1007860.g003
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In the second step, we calculated a cell-type modifier score as an indicator of the experi-
mental assay’s cell-specific nature. Briefly, we defined the prediction target using a top and bot-
tom quantile of Vodds (S5 Fig). Vodds is the standard deviation of log odds for each variant’s
read count in MPRA, which reflects the confidence interval of log odds ratio of an experiment.
Vodds shows cell line-specific patterns, as the patterns of the two B-Lymphocyte cell lines
(NA12878 and NA19239) are similar while distinct from HepG2 (S4 Fig) (see Methods for
details). This indicates that Vodds can capture the cell type-specific information. We also
found that variants with higher Vodds tend to include more non-emVARs (Chi-square test p-
Fig 4. Performance of the GRAM multi-step model. (a) ROC curve for regulatory activity prediction. (b) The prediction of the cell type modifier score using TF
expression profiles. (c) ROC for the model trained with both ChIP-Seq and SELEX DeepBind features on GM12878. (d) LASSO cross validation results with different
regularization parameters of the final GRAM generalized model using SELEX features on a multiple cell line dataset.
https://doi.org/10.1371/journal.pgen.1007860.g004
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value: 0.0002). Hence, the cell type modifier score defined from Vodds can be used to adjust
the universal regulatory effect to a cell type-specific context.
Gene expression profiles, especially TF expression profiles, are more generally available and
can represent the cellular environment. We incorporated TF gene expression and TF binding
scores as features to predict the cell type modifier target, and got an AUROC of 0.66 and 0.8
(Fig 4D), respectively, using Random Forest with a 10-fold cross-validation (Fig 4B and S6
Fig).
The final step is to predict the molecular effect of a variant, i.e. whether it can significantly
modulate reporter gene expression. To do this, we fed the output from the first and second
step into a LASSO model, with the emVAR and non-emVAR labels as targets. We found that
the AUROC of a 10-fold cross-validation for the optimal model was 0.724 (Fig 4C) and the
AUPRC was 0.602, both of which are higher than the state-of-the-art method (KSM) using the
same dataset (AUROC: 0.684, AUPRC: 0.478) [48].
To achieve better generalizability, we built the model with SELEX features only. We per-
formed step (i) and (ii) on the same GM12878 dataset and another multiple-cell-line dataset
(MCL dataset: GM12878 plus HepG2 plus K562). The model with cell-independent features
from the SELEX assay achieved comparable performance with an AUROC = 0.664 (GM12878
only) and 0.658 (MCL dataset, Fig 4D). We use the model based on the multiple-cell-line data-
set in our final GRAM model for a better generalization potential.
Validating the GRAM model using experimental assays
We next evaluated performance of the model on different cell types and assay platforms.
Rather than measuring read counts as in MPRA, some other assays, such as luciferase and
GFP reporter assays, measure luminescence and fluorescence readouts instead. [49, 50]. To
evaluate how our model, trained with multiple cell line MPRA data, can be transferred to these
assay platforms we tested its performance on luciferase assay results of eight potential regula-
tory elements with mutations from the MCF7 cell line [51]. To predict expression-modulating
effects, we defined the significant changes between alternative and reference alleles by using an
absolute log2(odds ratio) cutoff. The average AUROC value was greater than 0.8 for MCF7
(Fig 5A) and 0.67 for K562 given the an absolute log2 cutoff from 0.5 to 0.8 (Fig 5B). This indi-
cates that our model performs very well on the luciferase assay and MPRA dataset from differ-
ent cell lines, even though these assays use different measurements.
In MPRA, the element is inserted upstream (5’-terminal) of the reporter gene, but for some
assays, such as STARR-Seq, the element is inserted downstream (3’-terminal). Therefore, we
further tested the effect of insertion location of an element in luciferase reporters in K562 cells
using 14 randomly selected elements with potential regulatory activity. As shown in Fig 5C,
the 5’ terminal log odds were similar to the 3’ terminal odds for region 3, 4, 5, and 13, but
showed significant differences for region 6, 8, 9, 10, and 14. The prediction of GRAM for the 5’
terminal was much better than that for the 3’-terminal insertions; the AUROC was 0.25 higher
for universal regulatory activity and 0.32 higher for the expression-modulating effect predic-
tion, indicating different mechanisms for the two ends. Therefore, GRAM model is optimal
for 5’ terminal assays.
Expression modulating effect prediction for eQTL fine mapping
As GRAM needs only gene expression and SELEX DeepBind score to predict sample-wise var-
iants effect, it could be a flexible tool for a variety of analysis tasks. We investigated whether we
could apply our GRAM model to fine-mapping of causal variants. As was described in the
Methods part, we made a user-friendly pipeline GRAMMAR that could conduct the entire
Predictive model for the cell-specific molecular effect of non-coding variants
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analysis (S9 Fig). Here we mainly focused on the task of identifying the variants that are most
likely to directly modulate gene expression. For our analysis, we selected five LD blocks with
known risk association with prostate cancer and high enrichment of annotated eQTL SNPs
reported by Dadaev et al. [10], resulting in a set of 561 eQTL SNPs from the five LD blocks.
Fig 5. Experimental validation. (a) The AUROC value versus the different absolute log2 odds cutoff [0.5, 2.0] in the MCF7 cell line luciferase assay; The x-axis
represents the log odds ratio from the luciferase assay. (b) The AUROC value versus the different absolute log2 odds cutoff [0.5, 2.0] in K562 cell line luciferase assay; (c)
Experimental results (in odds ratio) for luciferase assay in K562 cell line. The 5’ terminal and 3’ terminal insertions are compared.
https://doi.org/10.1371/journal.pgen.1007860.g005
Predictive model for the cell-specific molecular effect of non-coding variants
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We extracted the genotypes and gene expression data from 102 The Cancer Genome Atlas
(TCGA) PRAD patients and ran GRAMMAR to get the prediction score for each allele in each
patient (S4 Table).
In general, variants with high posterior probability (�0.5, 130 variants), as a causal variant,
reported by Dadaev et al. [10], generally have higher average GRAM scores as compared to
those with lowest posterior probability (<0.5, 4260 variants) (p-value = 0.0545, S7 Fig). Specifi-
cally, we took a closer look at region chr6:160081543–161382029, tagged by GWAS SNP
rs9364554 and enriched with 52 eQTL SNPs for genes including ACAT2, LOC729603,
MRPL18, SLC22A3 and WTAP. All the FunSeq2 scores (maximum 1.40) are below 2, an
empirical threshold for confident candidate causal SNVs. GRAMMAR, however, can pinpoint
three SNV candidates with the highest average GRAM scores in this region (Fig 6A). Their
GRAM scores differ in different patient samples, indicating different expression modulating
effects of these SNVs under different personalized cellular contexts. Moreover, all three of the
highest-scored variants show strong correlations between the GRAM expression modulating
score and the expression of the related target gene and two of which are significant (p-
value < 0.05) (Fig 6B–6D).
Discussion
There has been an increasing number of computational methods that can prioritize non-cod-
ing variants. In addition, accumulating high-throughput whole-genome sequencing data have
become the primary source for identifying disease-associated variants. However, we still lack
an efficient prediction model for estimation of the expression-modulating effect of variants
that can be universally applied to many cell lines or samples. Previous studies tend to construct
one distinct model for each cell type, or predict the cell-type specificity of a variant from often
very limited experimental results (e.g. ChIP-Seq) in different cell types [25, 30, 52, 53], which
makes the generalization to other cell types challenging. In this study, we sought to represent
the impact of cellular environments on variant function from a different perspective. We
developed a multi-step generalized model called GRAM that can specifically predict the cell
type-specific expression-modulating effect of a non-coding variant in the context of a particu-
lar experimental assay. Our model receives both cell type-dependent and independent input
data and combines them with the same set of feature weights across different contexts, Thus,
our model can be applied to any cellular context as long as cell type- or sample-specific expres-
sion data are provided.
In this study, we aim to precisely define the expression-modulating effect as a function of
the predictive variables extracted from genomic data. In line with results from recent studies
[38, 39], a wide array of transcription-related features demonstrated high predictive power. In
contrast, three selected evolutionary features demonstrated low predictive power on used data-
sets. This pattern is likely due to the limited variety in evolutionary patterns in the training
data and also stems from the nature of GRAM, which focuses on predicting expression-modu-
lation effects. These effects are part of the many that are related to sequence conservation [54,
55]. In other words, the purpose of our model is to enable precise downstream analysis of
molecular effects of variants in a highly conserved region, where we would not expect conser-
vation scores to provide more additional information. We further selected a variety of TF
binding features that could be useful for predicting variant effects and used direct measure-
ments from TF binding scores and implemented a straightforward LASSO regression to assess
the importance of each feature. We found that in vitro SELEX TF features (aka non-cell-spe-
cific features) achieve the highest predictive performance, a result further validated by SVM
and Random Forest models trained in parallel.
Predictive model for the cell-specific molecular effect of non-coding variants
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We cannot ignore the cell type-specific context when predicting a variant’s effects. Usually,
a model can achieve cell type-specificity in two different ways: 1) building an independent
model for each cell line, or 2) building one unified model that can accept and handle specific
input data from any cell lines or samples. Which strategy to use depends on the availability of
Fig 6. Fine mapping of variants in prostate cancer. (a) General pipeline of the fine-mapping analysis. The first panel shows the position of the variants in the LD
block (chr6:160081543–161382029, tag SNP rs9364554). The second panel shows the FunSeq scores of these variants, where little variation and significance is observed.
The third panel shows the average GRAM score over the patients, with three highest-average-scored variants labelled in specific colors. Personalized GRAM scores for
the three highest-scored variants in three selected patients are presented subsequently. (b) ~ (d) Correlation between the GRAM score of variants with high scores and
the expression of relative target genes.
https://doi.org/10.1371/journal.pgen.1007860.g006
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the dataset and the demand for model transferability. Our model uses the second strategy, in
which cell type-specific information is incorporated as an input feature and the model learns
the same set of feature weights across multiple cell lines. For such a unified model, features like
histone modification and TF ChIP-Seq would limit its transferability because these features
may not be available for many other cell types or samples. Thus, we would prefer features that
are more easily available, such as gene expression profiles. Here, we built the model using cell
type-dependent gene expression and cell type-independent TF in vitro SELEX features; thus,
the model can be more easily applied to various different samples and cell lines. SELEX fea-
tures represent general binding strength of the TFs on the region of interest, and gene expres-
sion profiles can represent the specific cellular context.
The three-step GRAM model predicts the expression-modulating effects of variants by inte-
grating two intermediate predictive targets: universal regulatory activity and cell type modifier
score. The universal regulatory activity reflects the general regulatory effect of an element with
or without a mutation in a vector-based assay without considering cell type-specific chromatin
contexts or epigenomics information. Next, we modeled the cellular environment related to
gene regulation with a cell type modifier score, derived from cell type-specific TF expression
levels, to adjust the universal regulatory effect in the final step of the prediction model, greatly
improving the performance.
GRAM performed well in validations on MPRA and luciferase assay, even across different
cell types. In addition to target validations, our tool enables detailed exploration of the sensitiv-
ity of these methods and the impact of vector construct. The insertion position of the element
affected the outcome of the assay, which may correspond to different types of regulatory ele-
ments. Because our model is trained on 5’-terminal insertion data, the prediction is consistent
with outcomes from the same position, but not for 3’-terminal assay results. This indicates dif-
ferent mechanisms for two insertion positions: the assay with an element inserted upstream of
a reporter gene may detect either the promoter or enhancer activity of the element. However,
if the element is inserted downstream of the gene’s transcriptional start site or the 3’ terminal
in the assay, the reporter readout may be specifically to the enhancer activity of the element.
Large-scale experimental validation is required to further elucidate the underlying
mechanisms.
Our GRAM model can be further applied to fine mapping of functional SNVs. Particularly,
the prediction results of GRAM could aid in the identification of variants that are most likely
to directly modulate gene expression in a fine-mapping study. In addition, the impact of vari-
ants on gene regulation could vary across different cell types or individuals depending on dif-
ferential transcriptional factor activity, which is represented by the expression level of TFs in
our model. Based on this consideration, our model could potentially be used to evaluate the
molecular effect of variants in a sample-specific manner. Given a group of patients with paired
genotype and gene expression data, we could evaluate for each patient the expression-modulat-
ing effect of the variants of interest, which can be used to: 1) evaluate the patient-specific
expression modulating effect for each variant; 2) identify distinct expression modulating pat-
terns among the patient population; and 3) evaluate the overall variant effects by integrating
results from different patients. Such knowledge could potentially contribute to our under-
standing of the molecular mechanism underlying disease-association of variants, and guide
the characterization of patient-specific candidate variants for personalized diagnosis, progno-
sis and medical treatments.
In summary, our GRAM model will be a useful tool for elucidating the underlying patterns
of variants that modulate expression in a cell type- and tissue-specific context, and can be fur-
ther applied to different samples of the same cell type or tissue. By leveraging the accumulating
data generated from multiple cell lines, we can further improve for in-depth investigation in
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the future. We will keep abreast with the growing availability of comprehensive datasets and
further expand our analyses.
Methods
Dataset
We downloaded the dataset from R. Tewhey et al.’s paper [22, 23]. From about 79K tested ele-
ments, we only kept variants for which either reference or alternative allele elements show reg-
ulatory activity. This reduced the set to 3,222 SNVs in the GM12878 cell line and 1124 SNVs
in the HepG2 cell line. Each SNV was extended in both directions by 74bp, for a total of
149bp. We used another dataset from Ulirsch 2016 [17], which included 2,756 variants tested
in the K562 cell line.
The protein-protein interaction network used in our downstream analysis was constructed
by merging all interaction pairs identified by BioGrid [56], STRING [57] and InBio Map [58].
Feature extraction
GERP features were extracted using the FunSeq2 annotation pipeline, which averages over the
whole genome-scale GERP score over the elements. We downloaded phyloP [33] and Phast-
cons [34] scores from the UCSC genome browser data portal (http://hgdownload-test.cse.ucsc.
edu/goldenPath/hg19/).
We performed motif enrichment analysis using a hypergeometric test. To compare the
motif break and gain scores, we removed the TFs that covered less than two variants for either
emVARs or non-emVARs from the list of 40 TFs with the highest p-values in hypergeometric
test. Then, we performed a Wilcoxon test on the motif break score.
Motif break and motif gain scores were calculated using FunSeq2. We also calculated the
motif score using DeepBind [37] with both the SELEX and ChIP-Seq motif models. SELEX
motif models were identified from in vitro systematic evolution of ligands by an exponential
enrichment (SELEX) binding assay. ChIP-Seq models were inferred from sequences of TF
binding sites from different cell lines. A total of 515 motif models were investigated (S2 Table).
Model-based feature selection
To examine the importance of features, we compared different metrics learned from various
models including LASSO stability selection [42] and Random Forest regression. The feature
importance for each selection method was scaled to [0, 1]; we took the mean of all the selection
methods to represent the overall ranking.
We compared our models’ mean standard error (MSE) with CADD, Eigen, LINSIGHT,
FunSeq2, GWAVA, and DeepSea. Features from the above tools were collected and tested
using both SVR and Random Forest regression with three different input feature sets: SELEX-
based features, ChIP-Seq-based features, and SELEX- and ChIP-Seq-based features combined.
For other variant prioritization tools, we use their outputs as features to train the SVR and
Random Forest models to predict the logSkew value.
GRAM–multi-step generalized model
We labeled emVARs as positive and non-emVARs as negative classes following the definition
of [22], where ‘expression modulating’ means having a molecular effect that significantly
increases or decreases regulatory activities. We calculated the emVAR and non-emVAR for
both HepG2, GM12878 and K562 cell lines from [17] [22]. For emVAR and non-emVAR, we
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further filtered using logSkew with an absolute value >0.5849 (skew> 1.5). In total, we used
3,222 data records, including 799 positives and 2,423 negatives.
We built a three-step GRAM model (Table 1). Step 1 predicts the universal element regula-
tory activity U for both reference and alternative alleles. The ground-truth of regulatory activ-
ity is determined from results of experimental assay platforms, like a luciferase assay or
MPRA. In these assays, an element inserted into a plasmid, either with or without a mutation,
is characterized with regulatory activity if the fold change between the vector with the inserted
element and the control is larger than a statistically significant cutoff. Specifically, the predic-
tive target is defined as follows: for the MPRA study, where expression level of the reporter
gene is directly measured, a statistical test based on DESeq2 was used to indicate whether the
expression change is significant; for the luciferase assay, we regarded a testing element that has
a fold change of fluorescence level greater than 1.5 or 2 compared to control (like eGFP) as a
regulatory element. The predictive variable is the TF binding score from reference to alterna-
tive allele, which is estimated by DeepBind. A Random Forest classifier was then trained to
Table 1. Pseudocode of GRAM.
i: variant id
j: TF id
V: the total number of variants
N: the total number of TF
Bij: TF j binding score on variant i
Eij: Expression of j-th high-affinity TF on variant i
c: cell type or sample
Ui: Universal score for each i for for variant i
Sb(i,c): TF binding cell modifier score for variant i in sample c
Se(i,c): gene expression cell modifier score for variant i in sample c
M(i,c): molecular effect score for variant i in sample c
λ: the penalty term for the L1-regularization
b: the vector of coefficients, including bu,bs1,bs2,b0 for universal score, tf binding and gene expression modifier score
and noise repectively.
Step1: simple Universal score to be a regulatory element using randomForest classifier, U(i)2[0,1]
U(i) = F1(Bi1,Bi2,. . .,BiN),
Step2: TF binding and gene expression cell type modifier score, S(i,c)2[0,1] using randomForest
Sb(i,c) = F2(Bi1,Bi2,. . .,BiN)
Se(i,c) = F2(Ei1,Ei2,. . .,EiN)
Step3: molecular effect score, S(i,c)2[0,1]
bU ðimutÞ and bU ðiwtÞ are predicted from Step 1
bSb ði; cÞ and bSe ði; cÞ are predcited from Step2
dOdds ið Þ ¼ abs log2 bU ðimut Þ
1  bU ðimut Þ
=
bU ðiwt Þ
1  bU ðiwt Þ
� �� �
; dOdds ið Þ 2 0;/½ �
Mði; cÞ ¼ F3ðdoddsðiÞ, bSb i; cð Þ; bSe i; cð ÞÞ ¼ 1
1þe  1�ðbu
cOdds ðiÞþbs1bSb ði;cÞþbs2bSe ði;cÞþb0
, link function: logit
Objective function: minb 12V kbF   Fk
2
2
þ lkbk1, b = <bu,bs1,bs2,b0>
Time complexity for training: The complexity analysis for both Random Forest and LASSO depend on the
implementation. Simply, the Random Forest worse case training cost is O(MKN2logN) [59], where N is the total
number of rows, K is the number of split features for Random Forest, and M is the number of trees; the time
complexity of LASSO is O(K2N) and almost linearly in N when K�N, where N is the total number of rows, K is the
number of features [60].
https://doi.org/10.1371/journal.pgen.1007860.t001
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predict the universal regulatory activity. The predicted log odds of probability between the ref-
erence and alternative allele was calculated as log2 UðimutÞ
1  UðimutÞ
=
UðiwtÞ
1  UðiwtÞ
� �
.
Step 2 predicts the gene expression and TF binding cell type modifier scores. The cell type
modifier score is defined according to the cell specificity of the experimental assay. For each
variant, an MPRA experiment is performed on both the reference and alternative alleles, each
paired with a null-control, resulting in a 2x2 categorical table of read counts in the MPRA
experiments. The standard deviation of log(odds) of the categorical table (n1, n2, n3,n4 for the
average reads count, Table 2) is calculated as
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1
n1þ
1
n2þ
1
n3þ
1
n4
q
. For three different cell lines,
GM12878, GM19239, and HepG2, we constructed a vector of Vodds values for all the variants
that are tested. By comparing principal component loading of the Vodds from three cell lines,
we found that the two GM cell lines are closer to each other relative to HepG2 (S3 Fig), which
indicates that Vodds could reflect cell type information. We then further compared two groups
of variants above the top quartile and below the bottom quartile of Vodds in GM12878, and
found that there were more non-emVAR variants in the top quantile group, which indicates
that Vodds are also associated with the molecular effects of the variants. Based on these obser-
vations, we used the top and bottom quartile variants as positive and negative training sets,
respectively, to predict the cell type modifier target.
The TF expression profiles were used as input features for the prediction of the cell type
modifier class. For each mutation, we re-ordered the expression of TFs based on their binding
scores. Given 258 TFs with a DeepBind SELEX model score S for 3,222 SNVs, the TF expres-
sion matrix for each variant was adjusted and re-ordered using the rank of SELEX binding
scores of the TFs bound to these SNVs’ region. For each variant, this results in a vector reflect-
ing the expression of TFs relative to their binding strengths. That is, the first value in the vector
represents the adjusted expression of the most influential TF bound to this region, i.e. the one
with highest rank of binding scores, and so forth, regardless of what the TFs actually are. We
then used the TF binding score and re-ordered gene expression to predict the cell type modi-
fier label.
The final model predicts the molecular effect of a variant using the estimated universal
odds ratio and cell type modifiers from the two previous Steps. A LASSO model was used for
the prediction. The LASSO model trained with L1 regularization is more robust and tolerant
to noise. To achieve optimal predictive performance, we chose the regularization parameter
lambda λ that gives minimal mean cross-validated error.
Cross-validation
We hold out one-fold of same variants for all steps and perform a 10-fold cross-validation (S8
Fig). We first randomly permutate all the data by rows (variants), and split them into ten
evenly distributed subsets T (1, 2. . ., 10). We then iteratively hold out a subset Ti (i = 1, 2. . ., or
10), and make sure Ti are not used for training in any steps. We trained the model using the
remaining subset T−i (−i: excluding i), and predicted the results of Ti to get bTi . Finally, we
concatenated all bTis and evaluated the performance using AUROC and AUPRC.
Table 2. The 2x2 categorical matrix for computation of Vodds.
Reads Reference Alternative
Assay n1 n3
Null-control n2 n4
https://doi.org/10.1371/journal.pgen.1007860.t002
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Software
We integrated data processing pipelines and the final model into a software pipeline called
GRAMMAR (S9 Fig), published on (https://github.com/gersteinlab/GRAM). The user pro-
vides the variant list and gene expression data of each sample. The sequences with and without
the variants are then extracted from the hg19 genome and provided as input for DeepBind.
The GRAM model receives the DeepBind results and gene expression data and assigns a score
for each provided variant in each sample. Finally, the program outputs the sample-specific
GRAM scores for each sample, along with heatmap for all variants and samples. If variants
from multiple regions are provided, each region is plotted individually. The software is also
made available as a fine-mapping module to the more generalized FunSeq tool (FunSeq.ger-
steinlab.org), taking in the variants prioritized by the first tool and outputting the subset of
them that have a direct expression modulating function.
Fine mapping
The work by Dadaev et al. [10] reported 75 different LD blocks characterized by a known
GWAS risk association for prostate cancer. Some of the SNPs in these regions were found to
be significantly co-localized with identified eQTLs, annotated as eQTL SNPs. For our analysis,
we selected five regions with the largest number of eQTL SNPs, which in total contains 561
eQTL SNPs. Genotype and gene expression data for 102 TCGA PRAD patients were obtained
from the TCGA data portal. These data were then provided to the GRAMMAR pipeline
described above.
We plotted the estimated sample-wise GRAM scores for each region, and selected variants
with the highest average GRAM scores as assumed causal variants for expression modulation.
As a comparison, FunSeq [6] scores for each variant were also extracted based on position and
allele. To analyze the impact of these variants on gene expression, we calculated the Pearson
correlation between the sample-specific GRAM scores and expression of the target genes of
each eQTL variant.
Experimental validation on MCF7 cells
Each regulatory region (both reference and alternative alleles) was separately synthesized.
Enhancer regions were designed to include 250bp upstream and 250bp downstream for each
enhancer region based on the candidate SNV site. These regions were then cloned into the
pGL4.23[luc2/minP] vector (Promega, Cat# E841A). Each candidate region was placed
upstream of the minP promoter to determine the effect of each putative enhancer region on
luciferase expression. In total, 100ng of each candidate construct and 100ng of Nano-luc con-
trol was co- transfected into MCF-7 cells (5,000 cells per well in DMEM media containing 10%
FBS and 1% Penicillin-Streptomycin antibiotic) using the Lipofectamine 3000 reagent
(Thermo Fisher, Cat# L3000001) according to the manufacturer’s instructions. Cells were
incubated for 48 hrs before reading the luciferase signal using the Promega Nano-Glo lucifer-
ase kit (Promega, Cat# N1521) according to the manufacturer’s instructions.
Model validation using MPRA data from K562 cells
Enhancer selection. Based on the enhancer prediction and histone mark signaling over-
lap, we randomly selected 14 putative regulatory elements, and then randomly picked one or
two mutations based on FunSeq2 whole genome scores (http://funseq3.gersteinlab.org). Next,
we used a web tool to design site-directed mutagenesis primers to introduce the target SNVs
Predictive model for the cell-specific molecular effect of non-coding variants
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007860 August 30, 2019 17 / 23
into the 14 elements. Two SNVs were introduced into each element, with only one predicted
to result in a significant change in enhancer activity.
Reporter generation. Elements were amplified via PCR from human genomic DNA (Pro-
mega) with Platinum SuperFi polymerase (Invitrogen) and primers containing attB1 and attB2
sequences (see S3 Table). Elements were then cloned into pDONR223 using Gateway BP clo-
nase and transformed into E. coli cells. Four colonies for each element were picked and
sequenced via Sanger sequencing using the RV3 primer. One clone for each element with the
correct sequence was then cloned into pDEST-hSCP1-luc or pGL4-Gateway-SCP1 using Gate-
way LR clonase, and luciferase reporters containing the elements were then transfected into
K562 cells. pGL4-Gateway-SCP1 was a gift from Alexander Stark (Addgene plasmid # 71510)
[61]. To construct a positive control for the enhancer activity assays, we cloned the widely used
Rous sarcoma virus promoter that has been implied to possess enhancer activities.
Mutagenesis. The reference allele templates for site-directed mutagenesis were sequence-
verified entry clones containing putative regulatory elements. The mutagenesis primers con-
taining the pre-designed mutations were designed with a web tool (http://primer.yulab.org/).
The mutagenesis reactions were carried out following the Clone-Seq pipeline [62]. Each muta-
genesis reaction contained a reference allele template and its corresponding mutagenesis prim-
ers. The products of the mutagenesis reaction were DpnI-digested and transformed into
TOP10 chemically competent cells (Invitrogen). The transformants were spread on LB-specti-
nomycin agar plates and incubated at 37˚C overnight. Single colonies yielded from the muta-
genesis were picked, propagated, and sequence-verified before they were used in downstream
experiments.
Cell Lines. K562 cells were a gift from the Melnick lab (Weill Cornell Medicine). Cells
were cultured in Iscove’s Modified Dulbecco’s Medium (Gibco) supplemented with 10% FBS
and 1% Pen-Strep at 37˚C with 5% CO2.
Luciferase assay. K562 cells were transfected with 200 ng of the above reporters and 20 ng
of Renilla luciferase (pRL-CMV, Promega) in triplicate in 96-well plates with Lipofectamine
3000 (Invitrogen). At 48 hours post-transfection, luciferase activity was assayed with the Dual-
Glo Luciferase Assay System (Promega).
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